BioBlast® - Search
US | FDA approves Erbitux® (cetuximab) in combination with Braftovi® (encorafenib) for metastatic colorectal cancer
Eli Lilly announced that the FDA has approved Erbitux® (cetuximab) in combination with Braftovi® (encorafenib) for the treatment of metastatic colorectal cancer with a BRAF V600E mutation.
New study indicates pembrolizumab in combination with cetuximab shows promise as treatment for head and neck squamous cell carcinoma
A new study published in Lancet Oncology reported that pembrolizumab in combination with cetuximab shows promise as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.
NKMax and Merck KGaA expand clinical trial and supply agreement
NKMax and Merck KGaA announced an expansion of its clinical trial and supply agreement to include a Ph I/IIa trial of SNK01 in combination with Erbitux® (cetuximab) in patients with locally advanced or metastatic non-small cell lung cancer.
US | FDA approves new dosage regimen for Erbitux® (cetuximab)
The FDA approved a new dosage regimen for Erbitux® (cetuximab) for patients with K-RAS wild-type, EGFR-expressing metastatic colorectal cancer or squamous cell carcinoma of the head and neck. The new dosage regimen allows for fortnightly dosing.
AVEO reports data from Ph I study of ficlatuzumab and cetuximab
AVEO Oncology releases its Q2 FY2020 earnings report. AVEO reported data from its Ph I study of ficlatuzumab and cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC) demonstrated that the products have an acceptable safety profile and showed promising anti-tumour activity in a refractory HNSCC patient population. AVEO also announced that it is evaluating the process to secure additional clinical manufacturing of ficlatuzumab to potentially enable a Ph III clinical trial in 2022.
FDA approves encorafenib/cetuximab combination
Pfizer announces the FDA has approved Braftovi® (encorafenib) in combination with Erbitux® (cetuximab) for the treatment of BRAF600E-mutant metastatic colorectal cancer after prior therapy.
Pre-clinical study results of APZ 001
Researchers release results of pre-clinical study of cetuximab candidate APZ001.
Amgen discloses cetuximab biosimilar under development
Amgen discloses at JP Morgan Healthcare Conference that it is in process development for a cetuximab biosimilar.
MabTech announces successful Ph III trials of cetuximab
MabTech announces successful Chinese Ph III clinical trials for Sorrento’s “biosimilar/biobetter” cetuximab STI-001, and infliximab STI-002.
Product specific reports based on extracts from our BioBlast® database
BioBlast® Editor and Contributing Author
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.